**Specifications Table**TableSubject area*Pharmacy*More specific subject area*Pharmaceutical co-crystals*Type of data*Table and figure*How data was acquired*Fourier transform infrared (FTIR, Shimadzu FTIR-8300), differential scanning calorimeter (DSC, Shimadzu DSC-60) and high performance liquid chromatography (HPLC, Shimadzu LC-10 series) was used to analyze the product.*Data format*Analyzed, processed*Experimental factors--*Prepared co-crystals were stored in ambient conditions prior to analysis*--*Saturated solution was diluted by a factor of ten for solubility analysis within appropriate range*Experimental features*Preparation of co-crystals of Etravirine and L-tartaric acid in molar ratios 1:1, 1:2 and 2:1 with slow evaporation method. Solid state characterization of products using DSC and FTIR in addition to chemical stability analysis.*Data source location*Manipal, Karnataka, India*Data accessibility*Data are available in article*

**Value of the Data**•Mixture of L-tartaric acid and Etravirine shows different IR spectra compared to pure drug.•Further solubility studies of the co-crystals could investigate possible improved drug performance.•Chemical stability proved for molar ratio 1:1 and 1:2 of Etravirine and L-tartaric acid.

1. Data {#s0005}
=======

Data in this article shows the characteristics of products prepared from different molar ratios of Etravirine and L-tartaric acid. [Table 3](#t0015){ref-type="table"} shows the melting points of pure reactants and of the product samples and [Fig. 1](#f0005){ref-type="fig"} displays the complementary thermograms. [Fig. 2](#f0010){ref-type="fig"} displays the FITR spectra of the samples. All three sample batches prepared by slow evaporation method show a broadening of the primary amine peak (3300--3500 cm^-1^) whereas the physical mixture does not. Chemical stability data is shown in [Fig. 3](#f0015){ref-type="fig"} and [Table 4](#t0020){ref-type="table"} where the retention peak for Etravirine is the only area of significant size for both 0 and 7 days.Fig. 1Thermograms from DSC analysis of products of Etravirine: L-tartaric acid (A) 1:1 by slow evaporation method, (B) 1:2 by slow evaporation method, (C) 2:1 by slow evaporation and (D) 1:1 by physical mixture.Fig. 1Fig. 2FTIR spectra of samples containing Etravirine: L-tartaric acid in molar ratios (A) 1:1 by slow evaporation method, (B) 1:2 by slow evaporation method, (C) 2:1 by slow evaporation\* and (D) 1:1 by physical mixture. \*Only one of the three batches of molar ratio 2:1 showed a broadened peak around 3500--3300 cm^−1^.Fig. 2Fig. 3Chromatograms obtained from chemical stability analysis. A) 1:1, 0 days, B) 1:1, 7 days C) 1:2, 0 days D) 1:2, 7 days E) 2:1, 0 days F) 2:1, 7 days.Fig. 3

2. Experimental design, materials, and methods {#s0010}
==============================================

2.1. Materials {#s0015}
--------------

Etravirine was received from Apotex Research PVT LTD, Bangalore. L-tartaric acid was purchased from Sigma-Aldrich, Mumbai. HPLC grade acetonitrile was obtained and analytical grade methanol was obtained from FINAR Limited, Ahmedabad and acetone from Merck Life Sciences Private Limited, Mumbai. A Milli-Q purification system (Siemens AG, Germany) was used in the laboratory to obtain HPLC grade water.

L-tartaric acid was selected as co-former after promising results in increased solubility with DL-tartaric acid as co-former from a research study performed at Manipal College of Pharmaceutical Sciences during the fall of 2016 [@bib4]. Etravirine has 2 hydrogen bond donor sites and 7 hydrogen bond acceptor sites resulting in a high probability of co-crystal formation with co-formers.

2.2. Co-crystal preparation {#s0020}
---------------------------

Co-crystals were prepared in molar ratios 1:1, 1:2 and 2:1 of Etravirine and L-tartaric acid respectively through slow evaporation method. Desired amount of co-crystal component was weighed and saturated solutions of the components were prepared separately by adding approximately 1 mL solvent. The solvent used was acetone: methanol (50:50% v/v). The saturated solutions were mixed in a common vial and vortexed for 10 minutes. After, the solution was spread evenly on a petri dish and covered with aluminum foil with holes. The solution evaporated at room temperature until the sample was completely dry. The petri dish was scraped and the co-crystals were collected and stored for further analysis. 500 mg of co-crystals were produced in triplicate batches (*n*=3) for each molar ratio as described in [Table 1](#t0005){ref-type="table"}.Table 1Mass needed for 500 mg co-crystals in different ratios and number(name) of samples.Table 1**Etravirine:L-tartaric acid ratioEtravirine \[mg\]L-tartaric acid \[mg\]No. of samples prepared**1:1371.7128.331:2296.0204.032:1426.573.531:1 physical mix.371.7128.31

A single physical mixture sample of molar ratio 1:1 was also prepared in a plastic vial by mixing with a micro spatula for two minutes and then shaking the vial manually for five minutes.

2.3. Analysis {#s0025}
-------------

1.DSCShimadzu DSC-60 was used for obtaining DSC values. A single DSC sample consisting of all three batches was analyzed for each molar ratio. A sample of the physical mixture was also prepared, making 4 samples in total. 5 mg of each sample was placed in an aluminum bottom and crimped with an aluminum top. The test ran in the temperature range 30--350 °C with a temperature increase of 10 °C/min.2.FTIRA Shimadzu FTIR-8300 was used to acquire the FTIR spectra of the co-crystals. One FTIR sample per batch was prepared in addition to the physical mixture making 10 samples in total. The samples were dispersed in KBr which was then grinded to a disk by applying pressure. The measured range was 4000--500 cm^−1^ with 25 scans.3.HPLCThe co-crystal purity was analyzed with a Shimadzu LC-10 series chromatographic system. The system contained a controller unit (SCL-10A VP), a degasser unit (DGU-20A5), a quaternary gradient pump (LC-20AD), a refrigerated auto sampler (SIL-20AC HT) and a PDA detector (SPD-20A). The buffer solution was filtered using a vacuum-filtration apparatus (Alltech Associates) with a 0.45 μm filter (Pall Life Sciences). The mobile phase was degassed by sonication in Equitron ultrasonic bath. For the stationary phase a Hypersil BDS C~18~ (150×4.6 mm×5 μm) column was used and the mobile phase was a mixture of acetonitrile: phosphate buffer (60:40% v/v). The flow rate was 1 mL/min and detection wavelength at 304 nm at 30 °C.

2.4. HPLC sample preparation {#s0030}
----------------------------

The equivalent of 10 mg Etravirine in each co-crystal form was weighed out from a mixture of product batches with the same molar ratios. A stock solution was created by adding amount from [Table 2](#t0010){ref-type="table"} in 10 mL acetonitrile: methanol (50:50% v/v). 0.5 mL was pipetted from stock and diluted to 10 mL with the same solvent. 0.3 mL of diluted solution was further diluted with 1.2 mL acetonitrile: phosphate buffer (60:40% v/v). The product analysis was performed in triplicate (*n*=3) for each molar ratio.Table 2Mass of co-crystals needed for the equivalent amount of 10 mg Etravirine.Table 2**ETR:TAR compositionMass co-crystals weighed \[mg\]**1:113.51:216.92:111.7Table 3Literature values for melting points of components and DSC values for the co-crystal preparations. ETR is Etravirine, TAR is L-tartaric acid and CC stands for co-crystal.Table 3**SampleMelting endotherms \[°C\]**Etravirine260.36 [@bib5]L-tartaric acid171--174 [@bib6]1:1 ETR:TAR CC95.59 & 124.00 & 171.271:2 ETR:TAR CC170.65 & 196.732:1 ETR:TAR CC169.87 & 240.041:1 ETR:TAR physical mix174.09 & 252.43Table 4HPLC data for average area under curve for the Etravirine peak initially and after 7 days, as well as percentage assay.Table 4**Co-crystal sampleAverage area under curve, 0 days (*n*=3)Average area under curve, 7 days (*n*=2)% Assay**1:148273485333824110,51:226632063063559115,02:17999479604710975,6

2.5. Stability studies {#s0035}
----------------------

After 7 days, an additional HPLC test was run as described above on the co-crystals to examine their chemical stability and the possible appearance of degradation products. Samples were prepared in duplicates (*n*=2) for each molar ratio.
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